State of Wyoming Acquires New Shares in Kymera Therapeutics, Inc. $KYMR

State of Wyoming bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 11,780 shares of the company’s stock, valued at approximately $1,351,000.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after buying an additional 845,922 shares in the last quarter. State of New Jersey Common Pension Fund D bought a new position in Kymera Therapeutics during the 4th quarter valued at about $2,610,000. Maven Securities LTD bought a new position in Kymera Therapeutics during the 4th quarter valued at about $1,167,000. Eagle Health Investments LP bought a new position in Kymera Therapeutics during the 4th quarter valued at about $10,606,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Kymera Therapeutics in the fourth quarter worth approximately $7,781,000.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 31,283 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $109.48, for a total value of $3,424,862.84. Following the completion of the transaction, the director owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. This represents a 6.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the transaction, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at $28,151,749.68. This represents a 23.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 3,604,813 shares of company stock valued at $387,557,004. Company insiders own 15.98% of the company’s stock.

Analysts Set New Price Targets

KYMR has been the subject of several research reports. Mizuho boosted their price objective on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Bank of America raised their target price on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Morgan Stanley reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Truist Financial boosted their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Loop Capital set a $97.00 price target on Kymera Therapeutics in a report on Monday, June 8th. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $125.65.

Kymera Therapeutics Trading Up 2.6%

Kymera Therapeutics stock opened at $117.39 on Friday. Kymera Therapeutics, Inc. has a 12-month low of $39.84 and a 12-month high of $130.05. The firm has a market capitalization of $9.76 billion, a price-to-earnings ratio of -36.23 and a beta of 1.95. The firm has a 50 day moving average of $105.16 and a 200 day moving average of $90.28.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company’s revenue for the quarter was up 465.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. On average, analysts predict that Kymera Therapeutics, Inc. will post -3.78 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.